Syncom Formulations Reports Audited Financial Results for Year Ended March 31, 2026

Syncom Formulations Reports Audited Financial Results for Year Ended March 31, 2026​

Syncom Formulations (India) Limited has released its audited financial results for the quarter and year ended March 31, 2026. The results provide a comprehensive view of the company's performance across its operational segments and key financial metrics.

The financial reporting covers standalone and consolidated statements of results, along with the balance sheet and cash flow statements.

Financial Results Overview​

For the fiscal year ending March 31, 2026, the company reported robust financial performance across its segments.

Segment-Wise Revenue and Profit​

Syncom operates in three segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property.

The segment-wise data for the quarter ended March 31, 2026, shows the following revenue details:


Regarding profitability, the consolidated profit before tax for the period ended March 31, 2026, stood at 3,370.26 Rs. in Lacs, compared to 2,330.01 Rs. in Lacs in the previous year.

The segment profit details before tax for the same period are:

• Pharmaceuticals Drugs & Formulations: 3,371.66 Rs. in Lacs (FY2026) vs. 2,237.08 Rs. in Lacs (FY2025).
• Trading of Commodities: 4.39 Rs. in Lacs (FY2026) vs. 4.16 Rs. in Lacs (FY2025).
• Renting of Property: 40.54 Rs. in Lacs (FY2026) vs. 100.44 Rs. in Lacs (FY2025).

The Total Comprehensive Income for the period stood at 7,283.07 Rs. in Lacs for the year ended March 31, 2026, compared to 5,401.48 Rs. in Lacs for the previous year.

Standalone Financial Snapshot (Year Ended March 31, 2026)​

The company’s standalone financial statements reflect significant changes in asset composition. Total assets for the year ended March 31, 2026, were recorded at 53,384.52 Rs. in Lacs, up from 41,328.07 Rs. in Lacs in the previous year.

Key movements in the balance sheet include:

• Non-current assets: Increased from 40,968.66 Rs. in Lacs to 52,926.06 Rs. in Lacs.
• Current assets: Totaled 2,417.86 Rs. in Lacs.
• Equity: The 'Other Equity' increased to 32,098.83 Rs. in Lacs.

Cash Flow and EPS Analysis​

Cash Flow Highlights​

Analyzing the cash flow statement for the year ended March 31, 2026, shows the following cash generation figures:

• Cash From Operating Activities Net: Generated 5,807.93 Rs. in Lacs, compared to 2,343.61 Rs. in Lacs in the previous period.
• Cash From Investing Activities Net: Recorded (5,062.27) Rs. in Lacs, primarily driven by changes in Property Plant and Equipment and Investment Property.
• Cash From Financing Activities Net: Registered (302.17) Rs. in Lacs.

Earnings Per Share (EPS)​

Syncom reported that the comparative EPS for all preceding periods has been restated in accordance with Indian Accounting Standard 33. The restated Basic and Diluted EPS (for both discontinued and continuing operations) for the year ended March 31, 2026, was 0.81, which remained stable compared to the previous year's restated EPS of 0.81.

The restated EPS figures for the quarter ended March 31, 2026, are:

• Basic EPS (for discontinued & continuing operations): 0.27
• Diluted EPS (for discontinued & continuing operations): 0.27

SYNCOMF Stock Price Movement​

Today, Syncom Formulations (India) Limited shares edged higher to close at ₹14.34, gaining 0.77%. The equity saw robust trading volume today, tallying 1.61 million shares.